Connect with us

Hi, what are you looking for?

Tuesday, Sep 26, 2023
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.


Psilocybin advocates protest in Ottawa demanding fair medical access

The cohort led by TheraPsil will be meeting with parliament members and protesting outside the Centre Block

Psilocybin advocates protest in Ottawa demanding fair medical access
David Wood, Legal Advisor for TheraPsil; Janis Hughes, cancer patient and psilocybin advocate; Dr. Valorie Masuda; Elizabeth May, Member of Parliament; and Spencer Hawkswell, CEO of TheraPsil on Parliament Hill. Photo by Cam Saville via TheraPsil

A group of magic mushroom advocates ascended on Parliament Hill today to protest the strict and questionable policies surrounding psilocybin access for medical purposes.

The delegation of patients and medical professionals from across the country who arrived in the capital city on Monday are being led by TheraPsil, a non-profit organization dedicated to promoting fair access to psilocybin-assisted therapy in the country.

In addition to meeting with government officials and protesting, the participants from the psychedelic delegation will be taking part in media interviews and engaging in public events over the next three days to promote awareness about the medicinal value of psilocybin and the need for a more transparent regulatory approach to facilitate medical access going forward.

A gofundme campaign for the protest was created by Spencer Hawkswell, CEO of TheraPsil; and John Gilchrist, Communications & Training Specialist for the non-profit. So far the fundraiser has generated $5,400 since it began on November 15.

The fundraiser received substantial donations from Filament Health Corp (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS), Conscious Mind Clinic, Cybin Inc. (NEO: CYBN) (NYSE AMERICAN: CYBN), Apex Labs and many others.

Read more: U.S. senators introduce bill to improve access to psilocybin and MDMA

Read more: PsyCan pushes federal policy-makers to lift restrictions on psychedelics

Hawkswell said in a statement that there is ample evidence regarding the safety and efficacy of psilocybin for the treatment of a variety of mental health conditions.

“The previous Minister recognized this and started approving exemptions. Unfortunately, this Minister has stopped and refused to consider reasonable regulations to ensure vulnerable Canadians don’t have to go to Court to access treatment that can improve their quality of life and death,” added Hawkswell.

TheraPsil has supported Thomas Hartle, a cancer patient who was the first Canadian to be granted special access to psilocybin to help treat end-of-life anxiety. His application for the natural drug was approved by Minister Patty Hajdu in 2020 and his initial treatments were quite successful.

However, upon re-applying for access to more psilocybin through a section 56 exemption from the government in October 2021, his application was rejected by the new Health Minister, Jean Yves Duclos.

Hartle stated that Health Canada was lacking compassion for those in dire need of the medicine and wrongly denying access to people who are suffering.

Dr. Valorie Masuda presents on Parliament Hill. Photo by Cam Saville via TheraPsil

“It is cruel to withhold medicine from vulnerable patients, especially when those medicines have worked for them,” said Dr. Valorie Masuda, a palliative care physician at Cowichan District Hospital in Duncan, BC.

A full schedule of the group’s activities over the next three days can be found here.



Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Follow Rowan Dunne on Twitter

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like


It now has 19 million shares of the psychedelic drug developer, the firm's first investment in a public entity of this variety


The paper in the journal Psychopharmacology concluded that a machine learning algorithm could predict treatment efficacy


The clinical trials will examine the effects of the company's botanical psilocybin drug candidate PEX010


CYB003 is a molecule developed by the company with rapid onset and a short duration